Catalent Scientists to Present at Taiwan Key Technology Forum
Research Triangle Park, NC, July 26, 2010 – Ana T. Menendez, Ph.D., Senior Director of Biotechnology at Catalent Pharma Solutions, has been invited by the Taiwan Biotech Organization to lead a one-day workshop on GMP Bioassay Validation and GLP Immunogenicity Method Development on July 28, 2010. Dr. Menendez will also be delivering a podium presentation titled “Effective Transfer of Complex Biological Method” at the Key Technology Forum in Protein Drug Development, July 29, 2010. The Forum will focus on upstream process development, downstream process development, analytical and bioassay method development, formulation development and manufacturing, facility construction, and quality assurance and regulatory issues.
As Senior Director of Biotechnology at Catalent, Dr. Menendez is responsible for the release tests required to verify the functionality and purity of biotechnology products and the complex processes involved in their manufacture. Dr. Menendez implemented biotesting at Catalent and currently leads the following laboratories at the North Carolina Research Triangle Park facility: Cellular Technologies, Molecular Technologies, Virology and Analytical Biosafety. The expertise of the department ranges from proteins (i.e., monoclonal antibodies, enzymes, growth factors) to therapeutic viruses, bacterial vaccines and aptamers. Menendez is an international instructor on Bioassay Development and Validation and a frequent speaker at biopharmaceutical conferences.
For more information on Catalent’s broad range of biopharmaceutical development services including bioanalytical and immunogenicity development solutions, go to www.catalent.com/development.
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,000 people at 30 facilities worldwide and in fiscal 2009 generated more than $1.6 billion in annual revenue. For more information, visit www.catalent.com .